simvastatin therapy

Phase 2Small molecule

NNational Taiwan University Hospital

simvastatin therapy is one of 16 small molecule programs targeting Targeted Therapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Targeted TherapyRecruiting

Targeted TherapyPhase 2

Recruiting

Competition

Competitive Landscape

18 competitors in Targeted Therapy

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

2 2

Xospata

Astellas

Phase 3

2 3

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 4

Gazyva

Roche

Phase 2

1 5

Tafinlar

Novartis

Phase 2

1 6

Opdivo

Bristol-Myers Squibb

Phase 2

1 7

Braftovi

Pfizer

Phase 2

1 8

Fasenra

AstraZeneca

Phase 2

1 9

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 2

1 10

Tuoyi

CCoherus Oncology, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Targeted Therapy1 trial

Outcome-targeted Therapy: Principle and Outcome Evaluation: Clinical Study and Phenotype-genotype Correlation

Recruiting·NNational Taiwan University Hospital·Phase 2·NCT06632834·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for simvastatin therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — simvastatin therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for simvastatin therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Taiwan University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Taiwan University Hospital

simvastatin therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Targeted Therapy1 trial

References

Drug Info

Quick Facts

Related News